The first approved COVID-19 drug is far from ‘amazing’

Welcome to

Business Insider

s daily healthcare newsletter

, your daily dose of pharma, biotech, and healthcare news.

Subscribe here to get this newsletter in your inbox every weekday.

Pills 2 (2)


The coronavirus pandemic is overwhelming the US yet again, with the country recording its 2 worst-ever days of infection over the weekend.

“We are not going to control the pandemic,” White House Chief of Staff Mark Meadows said Sunday on CNN.

Also in healthcare news: Gilead’s set to make billions on a drug that’s far from “amazing”, AstraZeneca and Johnson & Johnson have restarted vaccine trials in the US, and universal masking could save 130,000.

Remdesivir2 by Getty Images
Vials of the drug Remdesivir pictured during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020, amidst the new coronavirus COVID-19 pandemic. ULRICH PERREY/POOL/AFP via Getty Images

Gilead is set to sell billions of dollars of a coronavirus drug that’s far from ‘amazing’ after the US approved remdesivir to treat COVID-19

Read the full story from Andrew Dunn here>>

Astrazeneca covid vaccine
Capped vials are being pictured during filling and packaging tests for the large-scale production and supply of the University of Oxfords COVID-19 vaccine candidate, AZD1222 VINCENZO PINTO/AFP via Getty Images

AstraZeneca and Johnson & Johnson get FDA green light to resume coronavirus vaccine trials in the US after participants got sick

Read the full story from Allana Akhtar here>>

President Donald Trump. AP Photo/Alex Brandon

Universal mask-wearing could save 130,000 US lives before March, mitigating the worst of this 3rd coronavirus surge

Read the full story from Aria Bendix here>>

More stories we’re reading:

Subscribe here for daily updates from the healthcare team!

– Lydia